NDC 50242-082

LUCENTIS

Ranibizumab

LUCENTIS is a Intravitreal Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Genentech, Inc.. The primary component is Ranibizumab.

• Product ID: 50242-082_115f8246-b87c-49aa-b411-e67afecdced9
• NDC: 50242-082
• Product Type: Human Prescription Drug
• Proprietary Name: LUCENTIS
• Generic Name: Ranibizumab
• Dosage Form: Injection, Solution
• Route of Administration: INTRAVITREAL
• Marketing Start Date: 2012-08-10
• Marketing Category: BLA / BLA
• Application Number: BLA125156
• Labeler Name: Genentech, Inc.
• Substance Name: RANIBIZUMAB
• Active Ingredient Strength: 6 mg/mL
• Pharm Classes: Vascular Endothelial Growth Factor Inhibitors [MoA],Vascular Endothelial Growth Factor Inhibitor [EPC]
• NDC Exclude Flag: N
• Listing Certified Through: 2020-12-31

Packaging

NDC 50242-082-01

1 VIAL, SINGLE-USE in 1 CARTON (50242-082-01) > .05 mL in 1 VIAL, SINGLE-USE

• Marketing Start Date: 2012-08-10
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 50242-082-02 [50242008202]

LUCENTIS INJECTION, SOLUTION

• Marketing Category: BLA
• Application Number: BLA125156
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: ML
• Marketing Start Date: 2016-11-28

NDC 50242-082-03 [50242008203]

LUCENTIS INJECTION, SOLUTION

• Marketing Category: BLA
• Application Number: BLA125156
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: ML
• Marketing Start Date: 2018-03-20

NDC 50242-082-87 [50242008287]

LUCENTIS INJECTION, SOLUTION

• Marketing Category: BLA
• Application Number: BLA125156
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: ML
• Marketing Start Date: 2017-02-28

NDC 50242-082-88 [50242008288]

LUCENTIS INJECTION, SOLUTION

• Marketing Category: BLA
• Application Number: BLA125156
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: ML
• Marketing Start Date: 2018-03-20

NDC 50242-082-01 [50242008201]

LUCENTIS INJECTION, SOLUTION

• Marketing Category: BLA
• Application Number: BLA125156
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: ML
• Marketing Start Date: 2012-08-10

Drug Details

Active Ingredients

Ingredient	Strength
RANIBIZUMAB	6 mg/mL

OpenFDA Data

• SPL SET ID: de4e66cc-ca05-4dc9-8262-e00e9b41c36d
• Manufacturer:
  • Genentech, Inc.
• UNII:
  • ZL1R02VT79
• RxNorm Concept Unique ID - RxCUI:
  • 1306074
  • 1864423
  • 1306076
  • 2045502
  • 2045501
  • 1864425
  • 643193
  • 644301

Pharmacological Class

• Vascular Endothelial Growth Factor Inhibitors [MoA]
• Vascular Endothelial Growth Factor Inhibitor [EPC]

Medicade Reported Pricing

50242082802 XOFLUZA 20 MG TAB (40 MG DOSE)

Pricing Unit: EA | Drug Type:

NDC Crossover Matching brand name "LUCENTIS" or generic name "Ranibizumab"

NDC	Brand Name	Generic Name
50242-080	LUCENTIS	RANIBIZUMAB
50242-082	LUCENTIS	RANIBIZUMAB
64406-019	Byooviz	ranibizumab
50242-078	Susvimo	Ranibizumab